ArticleFrontiers in neurology2025
Distinct serum endocannabinoid profiles in treatment-naïve Han Chinese children with ADHD: a case-control pilot study.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Although peripheral endocannabinoid system (ECS) signatures have been implicated in ADHD among European and American populations, evidence from Asian pediatric cohorts remains scarce. This study quantified serum concentrations of four major endocannabinoids-anandamide (AEA), 2-arachidonoylglycerol (2-AG), oleoylethanolamide (OEA), and palmitoylethanolamide (PEA)-in treatment-naïve Han Chinese children with ADHD and examined their associations with symptom severity as measured by the SNAP-IV scale. Methods: This cross-sectional study enrolled 22 children with ADHD (aged 6-12 years, diagnosed per DSM-5, IQ > 70) and 25 healthy controls (aged 6-12 years). Serum endocannabinoids were quantified via liquid chromatography-tandem mass spectrometry (LC-MS/MS). Symptom severity was assessed with SNAP-IV subscales [inattention, hyperactivity/impulsivity, oppositional defiant disorder (OD)]. Group comparisons used Results: Children with ADHD showed significantly lower OEA (1.21 ± 0.14 ng/mL vs. 1.65 ± 0.16 ng/mL) and PEA (0.69 ± 0.06 ng/mL vs. 0.86 ± 0.05 ng/mL) levels, higher 2-AG (1.94 ± 0.08 ng/mL vs. 1.72 ± 0.017 ng/mL, Conclusion: Selective ECS alterations in pediatric ADHD, particularly reduced OEA/PEA and elevated 2-AG with OEA's link to OD symptoms, may highlight potential blood-based biomarkers for diagnosis and monitoring, warranting further research into ECS-targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.